TMDX — TransMedics Group, Inc.
$91.38
$-0.62 (-0.67%)
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Market Cap
$3.17B
Forward P/E
36.8x
52-Week Range
TMDX Price History
Current price
$91.38
TMDX return (1Y)
-20.9%
S&P 500 return (1Y)
+12.2%
vs S&P 500
-33.2 pts
Revenue vs. Net Income
$605M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$134M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
12.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.8x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
9.8%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+15.1%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
